Following Lipectomy to Understand Adipose Tissue Re-accumulation
Launched by UNIVERSITY OF COLORADO, DENVER · Oct 13, 2009
Trial Information
Current as of June 14, 2025
Completed
Keywords
ClinConnect Summary
Lipectomy is the most frequently performed aesthetic surgery in the U.S. today and is considered permanent, by The American Society for Aesthetic Plastic Surgery, but no long term follow-up studies have been done to verify this assertion. Indeed, animal studies suggest rapid adipose tissue (AT) re-accumulation after lipectomy is common and may even be accompanied by unfavorable changes in disease risk. Recent studies in humans have focused on abdominal lipectomy as a means of reducing metabolic disease risk in obese premenopausal women. However, none of these studies evaluated AT re-accumul...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • post-menopausal (no menses for 12mo or oophorectomy w/ follicle-stimulating hormone (FSH)\>30 IU/L) OR- pre-menopausal (regular menses 28+/-3d)
- • BMI \>20 and \<30 kg/m2)
- • weight stable (+/- 2kg in past 2mo)
- • non-smoking
- • no use of hormone therapies or oral contraceptives
- • actively seeking liposuction of the hips and thighs
- • good femoral lipectomy candidates as determined by cosmetic surgeon
- Exclusion Criteria:
- • severe hypertriglyceridemia (\>400 mg/dL)
- • medications known to affect lipid metabolism
- • elevated resting blood pressure (Systolic \>140 mm Hg,Diastolic \>90 mm Hg)
- • history of lipectomy or gastric bypass surgery
- • body dysmorphic disorder
- • pregnant, lactating or intention of becoming pregnant
- • indication of high surgical risk (e.g., abnormal resting ECG, history of thromboembolism, valvular heart disease)
About University Of Colorado, Denver
The University of Colorado, Denver, is a leading academic institution dedicated to advancing medical research and improving healthcare outcomes. With a strong emphasis on innovation and collaboration, the university conducts a diverse range of clinical trials aimed at addressing critical health challenges. Its research initiatives are supported by a multidisciplinary team of experts, state-of-the-art facilities, and a commitment to ethical standards and patient safety. By fostering partnerships with local and global communities, the University of Colorado, Denver, strives to translate scientific discoveries into meaningful advancements in clinical practice and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aurora, Colorado, United States
Patients applied
Trial Officials
Rachael E Van Pelt, PhD
Principal Investigator
University of Colorado, Denver
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials